BHVNのROE（自己資本利益率）は？

BIOHAVEN LTD.のROEは-500.14%です。

BHVNの配当利回りは？

BIOHAVEN LTD.の配当利回りは0.00%です。

BHVNの品質スコア（Quality Score）は？

当社のAIはBHVNの総合財務品質を100点中46点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。

BHVNは今が買い時ですか？

当社AIのタイミングスコアは100点中70点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。

BHVNはどのセクターに属しますか？

BIOHAVEN LTD.はHealthcare >> Biotechnologyセクターに分類されます（NYSE市場）

BHVN (NYSE) 株価分析 | BIOHAVEN LTD.

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

BHVN AI Analysis Summary

Our AI summary for BHVN: BIOHAVEN LTD. (NYSE), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -500.14%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 70/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

BHVN

BIOHAVEN LTD.

US:NYSE STOCK Healthcare >> Biotechnology News 85

USD 13.50

-0.32 (-2.32%) Day Change

Watchlist Portfolio Compare Chart

1.91

D/E

-500.1%

ROE

-138.9%

ROA

0.00%

Div Yield

BIOHAVEN LTD.
TYPE: STOCK
MARKET: NYSE

Compare Watchlist Myport

USD 13.50 Price -0.32 (-2.32%) Day Change	NEWS SCORE: 85

BHVN, ファンダメンタルスコアはnot good ( ファンダメンタル = 46) but テクニカルスコアは ...(Sign In to See)...

Loading chart...

46 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Deepscope 分析

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	85
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	13.50
PBV / Sector	16.07 / 5.20
Earning Per Share	-4.20

PE / Sector	N/A / 19.97
PEG or PE/Growth / Sector	N/A / 1.22
Average 1M Daily Value	27.92 M GREAT
Average 1W Daily Value	23.87 M GREAT

Timing Factors

28%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

39%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

ポイントになる統計

37%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 98.71
NPM Average (%) / Sector	N/A / -1,721.76
NPM Change Average (%) / Sector	N/A / 5,211.62
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-138.87 / 27.02
ROA Average (%) / Sector	-121.17 / -368.17
ROA Change Average (%) / Sector	17.27 / 5,404.12 GOOD
ROE (%) / Sector	-500.14 / 3.47
ROE Average (%) / Sector	-464.02 / 6.51
ROE Change Average (%) / Sector	161.19 / 2,128.13 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

配当

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

登録情報

Analyze Date	2026-08-01 07:59:33
Symbol	BHVN
Name	BIOHAVEN LTD.
Sector	Healthcare >> Biotechnology
Market	NYSE
Listed Shares	150.56 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	2,080.75 / 9,903.94

ニュース

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 215 Church Street, New Haven, CT, United States, 06510

Phone: 203 404 0410

Website: https://www.biohaven.com

Employees: 274

Sector: Healthcare >> Biotechnology

Description: Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.